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Abstract
Background: A recent study has shown that it is possible to accurately estimate gestational age (GA) at birth from
the DNA methylation (DNAm) of fetal umbilical cord blood/newborn blood spots. This DNAm GA predictor may
provide additional information relevant to developmental stage. In 814 mother-neonate pairs, we evaluated the
associations between DNAm GA and a number of maternal and offspring characteristics. These characteristics
reflect prenatal environmental adversity and are expected to influence newborn developmental stage.
Results: DNAm GA acceleration (GAA; i.e., older DNAm GA than chronological GA) of the offspring at birth was
associated with maternal age of over 40 years at delivery, pre-eclampsia and fetal demise in a previous pregnancy,
maternal pre-eclampsia and treatment with antenatal betamethasone in the index pregnancy, lower neonatal birth
size, lower 1-min Apgar score, and female sex. DNAm GA deceleration (GAD; i.e., younger DNAm GA than
chronological GA) of the offspring at birth was associated with insulin-treated gestational diabetes mellitus (GDM)
in a previous pregnancy and Sjögren’s syndrome. These findings were more accentuated when the DNAm GA
calculation was based on the raw difference between DNAm GA and GA than on the residual from the linear
regression of DNAm GA on GA.
Conclusions: Our findings show that variations in the DNAm GA of the offspring at birth are associated with a
number of maternal and offspring characteristics known to reflect exposure to prenatal environmental adversity.
Future studies should be aimed at determining if this biological variation is predictive of developmental adversity.
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Background
Biomarkers of cellular aging have attracted increasing at-
tention over the past few years. Such biomarkers hold
the potential to identify individuals who are at risk of
aging-related diseases so that they may be offered timely,
targeted preventive interventions, hopefully decades be-
fore the onset of disease. DNA methylation (DNAm) is
an epigenetic mechanism characterized by the addition
of one methyl group primarily to cytosine-phosphate-
guanine (CpG) sites on DNA. The epigenome is known
to undergo age-related changes [1–6], and specific meth-
ylated CpG sites have been strongly correlated with
chronological age in humans. Hannum et al. identified
71 CpG sites in whole blood [7], and Horvath et al. iden-
tified 353 CpG sites from multiple tissues that could
predict chronological age with high accuracy (r > 0.91).
The median absolute difference between these methyla-
tion age biomarkers and chronological age has been
shown to vary from between 2.9 and 4.9 years [8]. Epi-
genetic age acceleration (AA; higher epigenetic than
chronological age) has been associated with negative
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health outcomes [9–11], and a recent meta-analysis of
over 13,000 individuals has confirmed that it can predict
all-cause mortality [12].
Epidemiological studies have shown that exposure to
adverse environmental events in the prenatal period pre-
dicts increased risk of aging-related diseases [13–18].
These studies are consistent with the Developmental Or-
igins of Health and Diseases (DOHaD) hypothesis [19],
which proposes that prenatal exposures alter develop-
mental trajectories [19]. However, it remains unclear
whether epigenetic AA could identify individuals at birth
who were exposed to environmental adversity in the pre-
natal period. A recent study assessed epigenetic AA in
peripheral blood from children and adolescents based on
the Hannum and the Horvath age predictors. In this
study, epigenetic AA, which was higher in boys, was also
associated with higher maternal body mass index (BMI)
and lower maternal selenium and cholesterol levels dur-
ing pregnancy, and higher birth weight of the offspring
[20]. Furthermore, epigenetic AA at birth measured in
DNA isolated from fetal cord blood was higher in the
offspring born to mothers who had smoked during preg-
nancy and who were delivered by cesarean section [20].
The Hannum and Horvath epigenetic age predictors
are not, however, suitable for epigenetic age estimation
using fetal cord blood. The Hannum age predictor was
based on whole blood taken from 19–101-year-old indi-
viduals [7] and the Horvath age predictor was based on
multiple tissues taken from 0–100-year-old individuals,
which includes fetal cord blood [8]. However, it should
be noted that the correlation of both predictors with
gestational age (GA) is nearly zero [20]. A recent study
generated a novel DNAm GA predictor designed specif-
ically for use on fetal umbilical cord blood or newborn
blood spots [21]. This predictor identified methylation of
148 CpG sites that showed a strong correlation (overall
r = 0.91) with ultrasound-based GA [21]. The average
absolute difference between the predicted DNA methyla-
tion GA and GA was 1.49 weeks [21]. Using fetal umbil-
ical cord blood samples, another recent study identified
96 and 58 CpG sites, which however correlated less
strongly with ultrasound-based (r = 0.81) and last men-
strual period-based GA (r = 0.71) [22]; Only 23 of the
ultrasound- and last menstrual period-based GA pre-
dictor CpG sites overlapped [22].
In the present study, we studied the DNAm GA pre-
dictor at birth based on fetal umbilical cord blood
methylation data as developed by Knight et al. [21]. We
tested whether DNAm GA is associated with a number
of maternal and offspring characteristics known to re-
flect a suboptimal prenatal developmental milieu of the
offspring. These characteristics include maternal pre-
pregnancy risk factors of pre-eclampsia and intrauterine
growth restriction, maternal pregnancy disorders,
maternal treatment with antenatal corticosteroids, parity
and mode of delivery, as well as newborn body size at
birth, cord blood pH, and Apgar score. For comparison,
we also present these associations with the Horvath epi-
genetic age, which shares only six overlapping CpG sites
with the DNAm GA predictor of Knight et al. [21].
Results
The associations of maternal and neonatal characteris-
tics with the raw DNAm GA difference (arithmetic dif-
ference between DNAm GA and GA) and with the
DNAm GA residual (the residual from a linear regres-
sion of DNAm GA on GA) were tested in 814 women
and their singleton neonates participating in the
Prediction and Prevention of Pre-eclampsia and
Intrauterine Growth Restriction (PREDO) study
(Additional file 1: Figure S1). The mean GA at birth of
this cohort was 39.76 (standard deviation (SD) 1.60; me-
dian 39.86; range 31.0–42.71) weeks, and the mean
DNAm GA at birth was 38.45 (SD 2.05; median 38.60;
range 28.50–47.13) weeks. There was a positive
correlation between the DNAm GA and GA (r = 0.51;
p < 0.0001; Fig. 1). The average absolute difference
(arithmetic difference between DNAm GA absolute
values and GA) between DNAm GA and GA was 1.78
(SD 1.41; median 1.51) weeks, and the raw mean
difference was −1.32 (SD 1.85; median −1.36; range
−10.64–6.97) weeks. There was a weak negative correl-
ation between the raw DNAm GA difference and GA
Fig. 1 Association between offspring DNAm gestational age (GA) at
birth based on cord blood methylation data and offspring chronological
ultrasound-based GA at birth. Scatterplot shows regression line and 95%
confidence intervals. p value refers to the significance level of
the association
Girchenko et al. Clinical Epigenetics  (2017) 9:49 Page 2 of 14
(r = −0.30; p < 0.0001). DNAm GA residual did not cor-
relate with GA (r = 0, p = 1.0).
Pearson correlations between the Horvath DNAm age
and our values were as follows: GA 0.03 (p = 0.32),
DNAm GA 0.11 (p = 0.002), raw DNAm GA difference
0.09 (p = 0.01), and DNAm GA residual 0.11 (p = 0.01).
Characteristics of the study population are presented
in Table 1.
Maternal characteristics during pregnancy and offspring
DNAm GA at birth
Figures 2, 3, and 4 show the associations between ma-
ternal characteristics during pregnancy with the raw
DNAm GA difference and the DNAm GA residual of
the offspring. The regression models are adjusted for
cellular heterogeneity and population stratification.
When based on the raw DNAm GA difference, GAA
was associated with a maternal age of above 40 years at
delivery, pre-eclampsia in a previous pregnancy, fetal
demise in a previous pregnancy, and having three or
more of the pre-pregnancy risk factors for pre-
eclampsia and intrauterine growth restriction (Fig. 2).
GAA was also associated with the presence, onset, and
severity of maternal pre-eclampsia in the index preg-
nancy and maternal treatment with betamethasone in
the index pregnancy, particularly if the treatment was
started a maximum of 30 days before delivery (Fig. 3).
GAD was associated with insulin-treated GDM in a
previous pregnancy (Fig. 2).
When based on the DNAm GA residual, GAA was as-
sociated with a maternal age of above 40 years at deliv-
ery, and GAD with insulin-treated GDM in a previous
pregnancy and maternal Sjögren’s syndrome (Fig. 4).
Additional file 2: Table S1 shows the unstandardized
regression coefficients and 95% confidence intervals for
the associations depicted in Figs. 2, 3, and 4 and for the
associations between the other tested maternal charac-
teristics during pregnancy and offspring DNAm GA at
birth. Additional file 2: Table S2 shows that all of the sig-
nificant associations remained significant when addition-
ally adjusted for the birth weight SD score based on
Finnish national growth references [23].
Additional file 2: Table S3 shows the associations be-
tween maternal characteristics and the offspring’s
Horvath epigenetic age at birth.
Offspring characteristics and DNAm GA at birth
GAA, based on the raw DNAm GA difference, was asso-
ciated with lower birth weight, birth length, ponderal
index at birth, birth head circumference, placental
weight (Fig. 5), being a lower birth weight for GA (con-
tinuous and being small-for-gestational-age, <−2 SD), a
lower 1-min Apgar score, and female sex (Fig. 6). All
models were adjusted for cellular heterogeneity,
population stratification, and additionally for sex in the
analyses of the offspring birth anthropometry.
When based on the DNAm GA residual, GAA was as-
sociated with a lower 1-min Apgar score and female sex
(Fig. 7). Additional file 2: Table S4 shows the unstan-
dardized regression coefficients and 95% Confidence In-
tervals for the associations depicted in Figs. 5, 6, and 7
and for the associations between the other tested off-
spring characteristics and offspring DNAm GA at birth.
Additional file 2: Table S5 shows the associations be-
tween offspring characteristics and the offspring Horvath
epigenetic age at birth.
Discussion
We show that a number of maternal and offspring char-
acteristics known to reflect the offspring’s exposure to
environmental adversity during the prenatal period were
associated with variations in the offspring’s DNAm GA
at birth. These characteristics are expected to influence
the newborn developmental stage and fetal organ and
tissue maturation. Characteristics associated with
DNAm GAA included a number of pre-eclampsia and
intrauterine growth restriction pre-pregnancy risk fac-
tors: maternal age of over 40 years, pre-eclampsia and
fetal demise in a previous pregnancy, and having a
higher number of pre-pregnancy risk factors of pre-
eclampsia and intrauterine growth restriction that were
measured in this study. DNAm GAA was also associated
with maternal pre-eclampsia in the index pregnancy and
treatment with antenatal betamethasone, which hastens
fetal lung maturation and maturation of some other tis-
sues [24]. It was also associated with a smaller body size
at birth and being born small-for-gestational age, lower
1-min Apgar score, and female sex. Furthermore, our
findings show that DNAm GAD was associated with
insulin-treated GDM in a previous pregnancy and
Sjögren’s syndrome. These findings were more accentu-
ated when the DNAm GA calculation was based on the
raw difference between DNAm GA and GA (which
shared 9% of variance with GA) than on the residual
from linear regression of DNAm GA on GA (which re-
moved the effect of GA entirely from DNAm GA, and
hence, was uncorrelated with GA). Our findings
emphasize that neonates exposed to prenatal environ-
mental adversity show differences at birth in their
DNAm GA and GA, confirmed by early pregnancy
ultrasound.
This conclusion is in agreement with a recent study,
which first generated the used biomarker for the epigen-
etic clock for GA at birth and tested associations be-
tween maternal socioeconomic status and newborn birth
weight with DNAm GA [21]. However, in contrast to
our findings, the previous study showed that DNAm
GAD was associated with mother’s socioeconomic
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Table 1 Characteristics of the study population (N = 814)
Maternal characteristics Mean (SD) or N (%)
Pre-pregnancy risk factorsa
Maternal age at delivery, years 33.3 (5.8)
Below 20 years, yes 22 (3.0%)
Above 40 years, yes 115 (14.1%)
Pre-eclampsia in previous pregnancy, yes 178 (21.9%)
Intrauterine growth estriction in previous pregnancy, yes 85 (10.4%)
Gestational diabetes in previous pregnancy, yes 84 (10.3%)
Diet treated 75 (9.2%)
Insulin treated 9 (1.1%)
Pre-pregnancy body mass index kg/m2 27.4 (6.4)
≥30 kg/m2 287 (35.3%)
Pre-pregnancy chronic hypertension, yes 109 (13.4%)
Pre-pregnancy type 1 diabetes, yes 12 (1.5%)
Pre-pregnancy systemic lupus erythematosus, yes 2 (0.3%)
Sjögren’s syndrome, yes 11 (1.4%)
Previous pregnancy with fetal demise (>22 gestational weeks or over 500 g), yes 28 (3.4%)
Number of known pre-pregnancy risk factors
No known pre-pregnancy risk factors 79 (9.7%)
1 or 2 pre-pregnancy risk factors 696 (85.5%)
3 or more pre-pregnancy risk factors 31 (3.8%)
Data not available 8 (1.0%)
Pregnancy disorders
Gestational diabetes, yes 183 (22.5%)
Diet treated 147 (18.1%)
Insulin treated 36 (4.4%)
Data not available on gestational diabetes treatment 2 (0.2%)
Data not available on gestational diabetes diagnosis 1 (0.1%)
Hypertension spectrum pregnancy disorders, yes
Gestational hypertension 80 (9.8%)
Pre-eclampsia 61 (7.5%)
Early pre-eclampsia (diagnosis <34 weeks of gestation) 53 (6.5%)
Late pre-eclampsia (diagnosis ≥34 weeks of gestation) 8 (1.0%)
Non-severe pre-eclampsia 42 (5.2%)
Severe pre-eclampsia 19 (2.3%)
Chronic hypertension 134 (16.5%)
Data not available 1 (0.1%)
Other characteristics
Education level
Lower secondary or less 359 (44.1%)
Upper secondary 184 (22.6%)
Tertiary 248 (30.5%)
Data not available 23 (2.8%)
Parity
Primiparous 247 (30.3%)
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Table 1 Characteristics of the study population (N = 814) (Continued)
Multiparous 566 (69.5%)
Data not available 1 (0.1%)
Smoking during pregnancy
Non-smoker 780 (95.8%)
Quit during first trimester 26 (3.2%)
Smoked throughout the pregnancy 8 (1.0%)
Data not available 0
Alcohol use during pregnancy
No 588 (72.2%)
Yes 117 (14.4%)
Data not available 109 (13.4%)
Mode of delivery
Vaginal 640 (78.6%)
Cesarean 173 (21.3%)
Data not available 1 (0.1%)
Antenatal betamethasone treatment
No 750 (92.1%)
Yes (n = 1 for 12 mg/24 h, n = 22 for 24 mg/24 h, n = 1 for 48 mg/24 h,
n = 11 for no information on dose)
35 (4.3%)
Timing of antenatal betamethasone treatment, number of days before birth 33.4 (27.1)
30 days or less before delivery 14 (1.7%)
30 days or more before delivery 13 (1.6%)
Data not available 29 (3.6%)
Neonatal characteristics
Sex
Girls 384 (47.2%)
Boys 430 (52.8%)
Data not available 0
Gestational age at birth, weeks 39.76 (1.60)
Data not available 0
DNA methylation gestational age, weeks 38.45 (2.05)
Data not available 0
Raw epigenetic gestational age difference, DNA methylation gestational
age-gestational age
−1.32 (1.85)
Data not available 0
Absolute epigenetic gestational age difference, DNA methylation
gestational age-gestational age in absolute values
1.78 (1.41)
Data not available 0
Horvath DNA methylation age at birth, weeks 9.77 (19.51)
Data not available 0
Birth weight, g 3549 (546)
Small for gestational age, yesb 23 (2.8%)
Data not available 1 (0.1%)
Birth length, cm 50 (2)
Small for gestational age, yesb 21 (2.6%)
Data not available 1 (0.1%)
Girchenko et al. Clinical Epigenetics  (2017) 9:49 Page 5 of 14
Table 1 Characteristics of the study population (N = 814) (Continued)
Head circumference, cm 35 (2)
Small for gestational age, yesb 14 (1.7%)
Data not available 2 (0.3%)
Ponderal index, kg/m3 27.8 (2.7)
Data not available 1 (0.1%)
Placenta weight, g 615 (134)
Cord blood pH
Arterial 7.26 (0.09)
Venous 7.31 (0.08)
Apgar score
9–10 611 (75.1%)
7–8 145 (17.8%)
≤6 47 (5.8%)
Data not available 11 (1.4%)
aPre-pregnancy risk factors served as inclusion criteria for the study as described [39]
bSmall for gestational age indicates birth size for sex and gestational age SD ≤ −2 according to Finnish growth references [23]
Fig. 2 Associations between maternal pre-pregnancy risk factors of pre-eclampsia and intrauterine growth restriction (panels a–e) and raw epigenetic
gestational age (GA) difference (DNAm GA-GA) of the offspring at birth based on fetal cord blood methylation data. Associations are adjusted for cell-
type composition and population stratification estimated with two multi-dimensional scaling components based on genome-wide data. Data shown
are median, interquartiles, and range. p values refer to group differences. Ref referent group
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disadvantage during pregnancy and the offspring’s lower
birth weight [21]. Also in contrast to our report, they re-
port no sex differences in the median errors between
DNAm GA and GA, i.e., boys and girls did not differ in
their DNAm GA at birth [21]. Another recent study,
which used the DNAm age predictors of Horvath and
Hannum on cord blood methylation data, also con-
cluded that prenatal adversity is associated with epigen-
etic age at birth [20]. Yet, of the 20 different maternal
and neonatal characteristics tested in that study, includ-
ing maternal age, education, alcohol use during preg-
nancy, body mass index (BMI), parity, birth weight, and
sex, only maternal smoking during pregnancy and
cesarean section were associated with epigenetic AA, in-
dependent of GA at birth. However, the Horvath and
Hannum epigenetic age did not correlate with the new-
born chronological GA [20, 21]. This supports our study,
as we found that the Horvath epigenetic age at birth
based on cord blood methylation data was uncorrelated
with the newborn GA. So, while the overall conclusion
from these prior studies is similar to ours, discrepancy
in the direction of associations indicates that future
studies are still needed. Yet, in effect size, the prior
findings and those of ours do not greatly differ. For in-
stance, in the Knight et al. study [21], offspring birth
weight accounted for 2% of the variance of the DNAm
GA, when accounting for GA and the other covariates;
in our study, birth weight was unrelated with DNAm
GA adjusted for GA, cellular heterogeneity, and popu-
lation stratification, but child’s sex accounted for 1%
and Apgar score accounted for 1% of the variance of
the DNAm GA. In the Simpkin et al. study [20], mater-
nal smoking during pregnancy and cesarean section
delivery explained less than 1% of the variance of off-
spring’s Horvath age at birth. In our study, these char-
acteristics and the offspring’s Horvath age at birth
were generally unrelated. Thus, future studies will
need to determine to what extent the different associa-
tions and their direction reflect differences between
the studies due to tissue type (cord blood plus new-
born blood spots vs cord blood only), cellular compos-
ition of samples, fetal cord blood contamination with
Fig. 3 Associations between maternal pregnancy disorders in the index pregnancy and other maternal characteristics (panels a–e) and raw
epigenetic gestational age (GA) difference (DNAm GA-GA) of the offspring at birth based on fetal cord blood methylation data. Associations have
been adjusted for cell-type composition and population stratification estimated with two multi-dimensional scaling components based on
genome-wide data. Data shown are median, interquartiles, and range. p values refer to group differences. Ref referent group
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maternal blood, and population genetic structure.
These factors were only taken into account in our
study. Differences may also relate to sample character-
istics: 89.3% of women in our sample had at least 1 of
the 10 pre-pregnancy risk factors of pre-eclampsia and
intrauterine growth restriction. This resulted in
greater variation in many maternal and offspring char-
acteristics, including GA and DNAm GA, which are
slightly different in this study from the study con-
ducted by Knight et al. [21].
Both DNAm GAA and GAD could be conceived as
indicators of risk. The increased risk of future adverse
outcomes associated with DNAm GAA is congruent
with findings in children and adults showing that epi-
genetic age acceleration is associated with a number of
adverse characteristics including higher BMI [25], lower
physical and cognitive fitness [26], and increased mor-
tality [9, 10, 12]. Lower developmental maturity, as in-
dicated by DNAm GAD, is consistent with the DOHaD
hypothesis and findings from previous studies showing
an increased risk of aging-related diseases in individuals
exposed to prenatal environmental adversity associated
with pre-term birth [27–31]. Hence, the associations
with DNAm GAA or GAD may serve as summary indi-
cators of epigenetic programming and indicate in-
creased risk for adverse outcomes later in life. As
suggested by Knight et al. [21], an alternative explan-
ation for the difference between DNAm GA and GA
may be the variable nature of the clinical GA estima-
tion. Yet, in our sample, this explanation may be less
likely as GA estimation in all women was based on
ultrasound performed between 12 + 0 and 13 + 6
gestational weeks + days.
However, it is important to note that when DNAm
GA was based on the residual, which removed the ef-
fect of GA on DNAm GA entirely, many of the mater-
nal and neonatal characteristics were no longer
associated with DNAm GA. Only a maternal age of
above 40 years, lower 1-min Apgar score, and female
sex were associated with residual GAA and insulin-
treated GDM in a previous pregnancy and maternal
Sjögren’s syndrome were associated with residual
GAD. If DNAm GA reflects developmental maturity,
we cannot rule out it being independent of various
environmental factors, which may alter the matur-
ational process. Associations may become more
evident later in childhood as the variation in methyla-
tion increases [3, 7, 32–34].
In our study, we used two measurements: raw DNAm
GA and residual DNAm GA. Residual DNAm GA was
corrected for any confounding effect of GA on DNAm
GA and hence did not correlate with GA. However, if
we had only focused on this variable, any finding which
was associated with both GA and DNAm GA would be
omitted, and hence, our analysis might have been too re-
strictive. Therefore, we decided to also present findings
from the raw DNAm GA in our study. These two mea-
sures of DNAm GAA and GAD might serve different
applications. The DNAm GA residual might be a more
appropriate measure for testing hypotheses on a popula-
tion level. As it is dependent on population characteris-
tics, it may not have clinical, individual level utility
Fig. 4 Associations between maternal pre-pregnancy risk factors of pre-eclampsia and intrauterine growth restriction (Panels a–c) and epigenetic
gestational (GA) residual (the residual from a linear regression of DNAm GA on GA) of the offspring at birth based on fetal cord blood methylation
data. Associations are adjusted for cell-type composition and population stratification estimated with two multi-dimensional scaling components
based on genome-wide data. Data shown are median, interquartiles, and range. p values refer to group differences
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unless population level “DNAm GA standards” become
available, analogous to national references for fetal
growth [23]. The raw DNAm GA difference may be a
more useful and clinically relevant measure for individ-
ual level assessments.
Strengths
The main strength of our study is the use of a well-
characterized prospective, ethnically homogenous cohort
with data on pre-pregnancy risk factors of pre-eclampsia
and intrauterine growth restriction, pregnancy disorders
Fig. 5 Associations between offspring anthropometry (panels a–d) and placental weight at birth (panel e) and raw epigenetic gestational (GA)
difference (DNAm GA-GA) of the offspring at birth based on fetal cord blood methylation data. Associations have been adjusted for cell-type
composition, population stratification estimated with two multi-dimensional scaling components based on genome-wide data, and neonatal sex.
Scatterplots show regression lines and 95% confidence intervals. p values refer to significance levels of the associations
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validated by a clinical jury consisting of two qualified
physicians and a nurse, and data on other maternal
and neonatal characteristics extracted from both med-
ical records and the Finnish Medical Birth Register
(MBR) [35]. Our sample was enriched for women with
known risk factors for pre-eclampsia and intrauterine
growth restriction. This resulted in greater variation of
the pre- and neonatal characteristics, thus increasing
the possibility of being able to detect their effects on
the DNAm GA predictor. Furthermore, clinical GA es-
timation was based on an ultrasound scan conducted
in all women between 12 + 0 and 13 + 6 weeks + days
of gestation. DNAm GA was estimated from fetal um-
bilical cord blood, and we applied novel methods to
account for any contamination of the samples by ma-
ternal blood. A number of studies have shown that cel-
lular heterogeneity [36], and genetic variation in the
population structure [37, 38], can influence epigenetic
profiles. Therefore, we removed any potential effects of
cell type heterogeneity using bioinformatics methods
and corrected for population structure using principal
components derived from genome-wide genotypes.
Limitations
Several strengths of this study are also limitations. The
ethnic homogeneity of our sample may preclude gener-
alizations for other ethnic groups. Our inclusion criteria,
which resulted in enrichment of pregnancy disorders in
Fig. 6 Associations between offspring small for gestational age (GA) weight at birth (panel a), sex (panel b), and Apgar score (panel c), and raw
DNAm GA difference (DNAm GA-GA) of the offspring at birth based on fetal cord blood methylation data. Associations are adjusted for cell-type
composition and population stratification estimated with two multi-dimensional scaling components based on genome-wide data. Data shown
are median, interquartiles, and range. p values refer to group differences. Ref referent group
Fig. 7 Associations between offspring sex (panel a) and Apgar score (panel b) and epigenetic gestational age (GA) residual (the residual from a
linear regression of DNAm GA on GA) of the offspring at birth based on fetal cord blood methylation data. Associations are adjusted for cell-type
composition and population stratification estimated with two multi-dimensional scaling components based on genome-wide data. Data shown
are median, interquartiles, and range. p values refer to group differences. Ref referent group
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the study population and increased statistical power to
detect their effects, also limit generalizability of these
findings to women without such risk factors. Finally, our
findings are limited to one tissue type; therefore, we
could not test cross-tissue correlations. It is also import-
ant to note that for some prenatal characteristics, e.g.,
for insulin-treated diabetes in a previous pregnancy, ma-
ternal Sjögren’s syndrome, less than ten pairs of women
and neonates were present in the risk group. Therefore,
although we observed significant associations, they
should be interpreted with caution and need to be repli-
cated. Finally, while maternal pre-eclampsia in the index
pregnancy, maternal treatment with betamethasone,
lower birth weight and length, and lower placental
weight remained associated with GAA after Bonferroni
correction for multiple testing, this correction may be
too conservative as the tested associations were not
independent.
Conclusions
Our findings show that a number of maternal and off-
spring characteristics known to reflect the offspring’s
prenatal environment are associated with variations in
the offspring’s DNAm GA at birth based on data from
cord blood DNA methylation. Whether this variation is
predictive of developmental outcomes in later life is the
subject of ongoing studies.
Methods
Study population
Data were taken from the PREDO study, which is a longi-
tudinal multicenter pregnancy cohort study of Finnish
women and their singleton children born alive between
2006 and 2010 [39]. We recruited 1079 pregnant women,
of whom 969 had 1 or more, and 110 had none of the
known risk factors for pre-eclampsia and intrauterine
growth restriction (Table 1). The recruitment took place
in arrival order when these women attended the first
ultrasound screening at 12 + 0–13 + 6 weeks + days of ges-
tation in 1 of the 10 hospital maternity clinics participat-
ing in the study. The cohort profile [39] contains details of
the study design, inclusion criteria, and all the data that
are available. Additional file 1: Figure S1 shows a flowchart
of the 814 mother-offspring pairs with data available for
the current study.
Offspring DNA methylation, GA, and DNAm GA at birth
Fetal cord blood samples were collected according to
standard procedures. DNA was extracted at the
National Institute for Health and Welfare, Helsinki,
Finland, and the Department of Medical and Clinical
Genetics, University of Helsinki, Finland. Methyla-
tion analyses were performed at the Max Planck
Institute of Psychiatry in Munich, Germany. DNA
was bisulphite-converted using the EZ-96 DNA
Methylation kit (Zymo Research, Irvine, CA).
Genome-wide methylation status of over 485,000
CpG sites was measured using the Infinium Human
Methylation 450 BeadChip (Illumina Inc., San Diego,
USA) according to the manufacturer’s protocol. The
arrays were scanned using the iScan System (Illu-
mina Inc., San Diego, USA). The quality control
(QC) pipeline was set up using the R-package minfi
(http://bioconductor.org/packages/release/bioc/html/
minfi.html). The samples were excluded if they were
duplicates, outliers in the median intensities, and be-
cause of sex discrepancy. Furthermore, any probes
on chromosome X or Y, cross-hybridizing probes as
well as probes containing SNPs, and CpGs with a
detection P value > 0.01 in at least 50% of the sam-
ples, or maternal blood contamination were ex-
cluded. Maternal blood contamination was tested
using DNAm data at 10 CpGs independently identi-
fied as differentially methylated between cord and
adult blood and indicative of maternal blood con-
tamination (paper under review). The samples with
DNAm values above the previously identified thresh-
olds at five or more of these CpGs were considered
contaminated and removed from all future analyses.
The final dataset contained 428,619 CpGs. Additional
file 1: Figure S1 shows that of the 876 samples avail-
able for these analyses, 51 were excluded. Methylation
beta-values were normalized using the funnorm func-
tion and incorporating the first ten principal compo-
nents from the internal control probes. To check for
batch effects, principal components were computed on
these beta values. Two batches, i.e., slide and well,
were significantly associated to the main principal
components and were removed iteratively using the
combat package.
DNAm GA was calculated using the method pub-
lished by Knight et al. [21] and was based on the
methylation profile of 148 selected CpGs.
We calculated a raw DNAm GA difference by sub-
tracting the chronological GA assessed at the first
ultrasound screening conducted at 12 + 0–13 + 6 weeks
+ days of gestation from the predicted DNAm GA.
DNAm GA residual was extracted from a linear regres-
sion of predicted DNAm GA on ultrasound-based GA.
Offspring cord blood cell counts at birth
Seven cell types (nucleated red blood cells, granulo-
cytes, monocytes, natural killer cells, B cells, CD4(+)T
cells, and CD8(+)T cells) were estimated from cord
blood methylation using the method of Bakulski et al.
[40] which was also incorporated in the R-package
minfi.
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Offspring genome-wide genotyping and multi-dimensional
scaling analysis
Genotyping was performed on Illumina Human Omni
Express Exome Arrays containing 964,193 SNPs. Only
markers with a call rate of at least 98%, a minor allele
frequency of 1%, and a P value for deviation from
Hardy-Weinberg-Equilibrium (P > 1.0 e-06) were kept in
the analysis. After QC, 587,290 SNPs were available.
Any sample pair with IBD estimates >0.125 was checked
for relatedness. For most pairs, high IBD estimates could
be explained due to partly African origin. As we cor-
rected for admixture in our analyses, these samples were
kept except for one pair. For this pair, the high IBD esti-
mate could not be resolved and the other one of this
pair was excluded from further analysis. The samples
showing discrepancies between phenotypic and geno-
typic sex were removed. We also checked for heterozy-
gosity outliers, but found none. In total, we genotyped
996 samples of which 13 were excluded. Of the samples
with DNA methylation data, eight were excluded based
on the above criteria (Additional file 1: Figure S1).
We performed multi-dimensional scaling (MDS) ana-
lysis on the IBS matrix of quality-controlled genotypes.
Apart of those samples with African admixture, no out-
liers were detected. The first two components depict this
admixture and were included as covariates in the regres-
sion analysis.
Maternal characteristics during pregnancy
Pre-pregnancy risk factors of pre-eclampsia and intra-
uterine growth restriction were derived from medical re-
cords screened for by trained study nurses or clinic
personnel at maternity clinics of study hospitals at enrol-
ment into the study. These pre-pregnancy risk factors
are listed in Table 1.
Pregnancy disorders, derived from hospital records
and further verified by a clinical jury [39, 41], in-
cluded gestational diabetes, which was defined as
fasting, 1- or 2-h plasma glucose during a 75-g oral
glucose tolerance test ≥5.1, 10.0 or 8.5 mmol/L, re-
spectively, that emerged or was first identified during
pregnancy, and further categorized according to
treatment as diet or insulin treated; gestational
hypertension, which was defined as systolic blood
pressure ≥140 mmHg and/or diastolic blood pressure
≥90 mmHg on ≥2 occasions at least 4 h apart in a
woman who was normotensive before 20 weeks of
gestation; pre-eclampsia, which was defined as sys-
tolic blood pressure ≥140 mmHg and/or diastolic
blood pressure ≥90 mmHg on ≥2 occasions at least
4 h apart with proteinuria ≥300 mg/24 h. Pre-
eclampsia diagnosis was further divided into early
(diagnosis before 34 weeks of gestation) and late
pre-eclampsia (diagnosis 34 weeks of gestation or
later), and also into severe (blood pressure
≥160 mmHg systolic and/or ≥110 mmHg diastolic
and/or proteinuria ≥5 g/24 h) and non-severe pre-
eclampsia (blood pressure 140–159.9 mmHg systolic
and/or 90–109.9 mmHg diastolic and/or proteinuria
0.3–4.9 g/24 h); chronic hypertension was defined as
systolic/diastolic blood pressure ≥140/90 mmHg or
antihypertensive medication before 20 weeks of ges-
tation (in 24 out of 135 women chronic hypertension
was diagnosed during pregnancy). In addition to pre-
pregnancy obesity, data on maternal pre-pregnancy
BMI calculated from measured weight and height at
the first antenatal clinic visit at 8 + 4 (SD 1 + 3)
weeks + days were derived from the Finnish Medical
Birth Register (MBR) [35] and data on weight change
during pregnancy from medical records.
Information on the antenatal corticosteroid (beta-
methasone) treatment was derived from hospital
records (one woman received half a standard dose, i.e.,
12 mg/24 h, 22 women received one standard dose of
24 mg/24 h, and one woman received two standard
doses totalling 48 mg/24 h), and timing of exposure
was further defined as the number of days before birth
(over 30 vs 30 days or less before birth).
Maternal smoking during pregnancy (non-smoker, quit
during first trimester, smoked throughout), parity (prim-
iparous vs multiparous) and mode of delivery (vaginal
delivery vs caesarian section) were derived from the
MBR, and alcohol use (yes vs no) and education level
(lower secondary or less, upper secondary, tertiary) were
reported at 12 + 0–13 + 6 gestational weeks + days.
Offspring characteristics at birth
Weight (kg), length (cm), head circumference (cm), fetal
cord blood venous and arterial pH, and 1-min Apgar
score were measured at birth, and the birth ponderal
index (kg/m3) was calculated. We further divided birth
weight and length into normal and small (≤ − 2SD) for
GA using Finnish national growth references [23].
Statistical analysis
We tested the associations between maternal and off-
spring characteristics with the raw DNAm GA differ-
ence, DNAm GA residual, and Horvath epigenetic age
with linear regressions. All models were adjusted for
cell-type composition and population stratification esti-
mated with two multi-dimensional scaling components
based on genome-wide data. Maternal characteristic data
were further adjusted for birth weight SD score and neo-
natal anthropometric data for child’s sex. Unstandard-
ized regression coefficients and 95% confidence intervals
(CI) represent effect sizes in weeks (raw DNAm GA dif-
ference and Horvath epigenetic age) and SD units with a
mean of 0 and SD 1 (DNAm GA residual). Nominal 2-
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tailed p values are given in the tables and Bonferroni-
corrected p value threshold reaching a level of p < 0.05
in footnotes. All statistical analyses were performed
using SAS 9.4 (SAS Institute, Inc., Cary, NC, USA).
Additional file
Additional file 1: Figure S1. Flowchart of the study participants and
sample attrition. (PPTX 38 kb)
Additional file 2: Table S1. Associations between maternal
characteristics during pregnancy and offspring DNAm GA at birth based
on cord blood methylation data. Table S2. Associations between
maternal characteristics during pregnancy and offspring DNAm GA at
birth based on cord blood methylation data when additionally adjusting
for offspring birth weight SD score at birth*. Table S3. Associations
between maternal characteristics and the offspring Horvath epigenetic
age at birth based on cord blood methylation data*. Table S4.
Associations between offspring characteristics and DNAm GA at birth
based on cord blood methylation data. Table S5. Associations between
offspring characteristics and the offspring Horvath epigenetic age at birth
based on cord blood methylation data*. (DOCX 65 kb)
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